Braidwell LP Invests $4.76 Million in Metsera Inc. $MTSR

Key Points

• Braidwell LP has made a new investment in Metsera Inc., acquiring 175,000 shares valued at approximately $4.76 million during the first quarter.
• Several major institutional investors, including Alphabet Inc. and T. Rowe Price, have also bought significant stakes in Metsera during the same period, indicating strong institutional interest.
• Wall Street analysts have raised their price targets for Metsera shares, with Bank of America increasing its target from $45 to $50, while Guggenheim increased it from $56 to $62, both maintaining a "buy" rating.

Braidwell LP bought a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 175,000 shares of the company's stock, valued at approximately $4,764,000. Braidwell LP owned about 0.17% of Metsera at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. New York State Common Retirement Fund purchased a new stake in shares of Metsera during the 1st quarter valued at $131,000. Corebridge Financial Inc. purchased a new stake in shares of Metsera during the 1st quarter valued at $206,000. MetLife Investment Management LLC purchased a new stake in shares of Metsera during the 1st quarter valued at $254,000. Invesco Ltd. purchased a new stake in shares of Metsera during the 1st quarter valued at $271,000. Finally, Deutsche Bank AG purchased a new stake in shares of Metsera during the 1st quarter valued at $374,000.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MTSR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a research report on Wednesday. Bank of America lifted their price objective on Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Guggenheim lifted their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wall Street Zen raised Metsera from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Finally, Wells Fargo & Company initiated coverage on Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Metsera presently has a consensus rating of "Buy" and an average target price of $59.00.

Metsera Price Performance

Shares of MTSR stock traded down $0.42 during trading hours on Friday, reaching $35.87. The company's stock had a trading volume of 1,520,674 shares, compared to its average volume of 1,208,677. Metsera Inc. has a one year low of $12.30 and a one year high of $47.40. The firm's fifty day simple moving average is $34.73 and its 200 day simple moving average is $28.67.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.